Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Oct
08
Today In Oncology
Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste
Federally Funded Clinical Trials Play a Vital Role in Cancer Research, Especially for Rare and Pediatric Cancers
Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress
Breast Volume Preservation Comparable After Five-Fraction Whole- or Partial-Breast Radiotherapy
Genetic Modification of the AJCC Classification for Papillary Thyroid Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo